- Home
- PCRX vs AUTL Comparison
PCRX vs AUTL Comparison
Compare PCRX & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- AUTL
- Stock Information
- Founded
- PCRX 2006
- AUTL 2014
- Country
- PCRX United States
- AUTL United Kingdom
- Employees
- PCRX N/A
- AUTL N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PCRX Health Care
- AUTL Health Care
- Exchange
- PCRX Nasdaq
- AUTL Nasdaq
- Market Cap
- PCRX 1.2B
- AUTL 625.4M
- IPO Year
- PCRX 2011
- AUTL 2018
- Fundamental
- Price
- PCRX $23.22
- AUTL $2.37
- Analyst Decision
- PCRX Buy
- AUTL Strong Buy
- Analyst Count
- PCRX 9
- AUTL 5
- Target Price
- PCRX $29.89
- AUTL $9.32
- AVG Volume (30 Days)
- PCRX 560.0K
- AUTL 2.1M
- Earning Date
- PCRX 07-29-2025
- AUTL 08-07-2025
- Dividend Yield
- PCRX N/A
- AUTL N/A
- EPS Growth
- PCRX N/A
- AUTL N/A
- EPS
- PCRX N/A
- AUTL N/A
- Revenue
- PCRX $702,772,000.00
- AUTL $9,011,000.00
- Revenue This Year
- PCRX $7.54
- AUTL $461.76
- Revenue Next Year
- PCRX $10.78
- AUTL $112.66
- P/E Ratio
- PCRX N/A
- AUTL N/A
- Revenue Growth
- PCRX 3.08
- AUTL N/A
- 52 Week Low
- PCRX $11.16
- AUTL $1.11
- 52 Week High
- PCRX $27.64
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- PCRX 34.52
- AUTL 70.63
- Support Level
- PCRX $22.82
- AUTL $2.20
- Resistance Level
- PCRX $24.36
- AUTL $2.44
- Average True Range (ATR)
- PCRX 0.69
- AUTL 0.12
- MACD
- PCRX -0.12
- AUTL -0.01
- Stochastic Oscillator
- PCRX 12.39
- AUTL 84.95
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.